Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH; CARDS Investigators.

Am J Kidney Dis. 2009 Nov;54(5):810-9. doi: 10.1053/j.ajkd.2009.03.022. Epub 2009 Jun 21.

PMID:
19540640
3.

Atorvastatin: its clinical role in cerebrovascular prevention.

Gaspardone A, Arca M.

Drugs. 2007;67 Suppl 1:55-62. Review.

PMID:
17910521
4.

Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.

Plosker GL, Lyseng-Williamson KA.

Pharmacoeconomics. 2007;25(12):1031-53. Review.

PMID:
18047388
6.

Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin.

Bybee KA, Lee JH, O'Keefe JH.

Curr Med Res Opin. 2008 Apr;24(4):1217-29. doi: 10.1185/030079908X292001 . Epub 2008 Mar 20. Review.

PMID:
18358084
7.

Management of dyslipidemias in patients with diabetes and chronic kidney disease.

Molitch ME.

Clin J Am Soc Nephrol. 2006 Sep;1(5):1090-9. Epub 2006 Jul 26. Review.

8.

Statins for improving renal outcomes: a meta-analysis.

Sandhu S, Wiebe N, Fried LF, Tonelli M.

J Am Soc Nephrol. 2006 Jul;17(7):2006-16. Epub 2006 Jun 8. Review.

9.

Meta-analysis: the effect of statins on albuminuria.

Douglas K, O'Malley PG, Jackson JL.

Ann Intern Med. 2006 Jul 18;145(2):117-24. Review.

PMID:
16847294
10.

Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus.

Riche DM, McClendon KS.

Am J Health Syst Pharm. 2007 Aug 1;64(15):1603-10. Review.

PMID:
17646562
11.

Statins and CVD prevention in the diabetic population: implications of the CARDS trial.

Murad O, Palmer J, Sowers J, McFarlane SI.

Curr Diab Rep. 2005 Jun;5(3):191-3. Review. No abstract available.

PMID:
15929865
12.

Expanding roles for atorvastatin.

Singh V, Deedwania P.

Drugs Today (Barc). 2008 Jun;44(6):455-71. doi: 10.1358/dot.2008.44.6.1217468. Review.

PMID:
18596999
13.

Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis.

Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN.

Am J Kidney Dis. 2010 May;55(5):835-47. doi: 10.1053/j.ajkd.2009.11.013. Epub 2010 Jan 29. Review.

PMID:
20110146
14.

Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).

Sever PS, Poulter NR, Dahlöf B, Wedel H; Anglo-Scandinavian Cardiac Outcomes Trial Investigators.

Am J Cardiol. 2005 Sep 5;96(5A):39F-44F. Review.

PMID:
16126022
15.

Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria.

Anavekar NS, Gans DJ, Berl T, Rohde RD, Cooper W, Bhaumik A, Hunsicker LG, Rouleau JL, Lewis JB, Rosendorff C, Porush JG, Drury PL, Esmatjes E, Raz I, Vanhille P, Locatelli F, Goldhaber S, Lewis EJ, Pfeffer MA.

Kidney Int Suppl. 2004 Nov;(92):S50-5. Review.

PMID:
15485418
16.

What's in the CARDS?

Plummer CJ.

Diabet Med. 2006 Jul;23(7):711-4. Review. No abstract available.

PMID:
16842473
17.

Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline.

Slinin Y, Ishani A, Rector T, Fitzgerald P, MacDonald R, Tacklind J, Rutks I, Wilt TJ.

Am J Kidney Dis. 2012 Nov;60(5):747-69. doi: 10.1053/j.ajkd.2012.07.017. Epub 2012 Sep 19. Review.

PMID:
22999165
18.

[Atorvastatin in secondary prevention].

Ongen Z, Yilmaz Y, Karadağ B.

Turk Kardiyol Dern Ars. 2009 Mar;37 Suppl 2:23-8. Review. Turkish.

19.

Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy.

Athyros VG, Mitsiou EK, Tziomalos K, Karagiannis A, Mikhailidis DP.

Expert Opin Pharmacother. 2010 Apr;11(5):723-30. doi: 10.1517/14656560903575654. Review.

PMID:
20210681
20.

Should eGFR and albuminuria be added to the Framingham risk score? Chronic kidney disease and cardiovascular disease risk prediction.

Chang A, Kramer H.

Nephron Clin Pract. 2011;119(2):c171-7; discussion c177-8. doi: 10.1159/000325669. Epub 2011 Jul 28. Review.

Items per page

Supplemental Content

Write to the Help Desk